Journal article icon

Journal article

Assessing the value of incorporating a polygenic risk score with nongenetic factors for predicting breast cancer diagnosis in the UK Biobank

Abstract:

Background: Previous studies have demonstrated that incorporating a polygenic risk score (PRS) to existing risk prediction models for breast cancer improves model fit, but to determine its clinical utility the impact on risk categorization needs to be established. We add a PRS to two well-established models and quantify the difference in classification using the net reclassification improvement (NRI).

Methods: We analyzed data from 126,490 post-menopausal women of “White British” ancestry, aged 40 to 69 years at baseline from the UK Biobank prospective cohort. The breast cancer outcome was derived from linked registry data and hospital records. We combined a PRS for breast cancer with 10-year risk scores from the Tyrer–Cuzick and Gail models, and compared these to the risk scores from the models using phenotypic variables alone. We report metrics of discrimination and classification, and consider the importance of the risk threshold selected.

Results: The Harrell's C statistic of the 10-year risk from the Tyrer–Cuzick and Gail models was 0.57 and 0.54, respectively, increasing to 0.67 when the PRS was included. Inclusion of the PRS gave a positive NRI for cases in both models [0.080 (95% confidence interval (CI), 0.053–0.104) and 0.051 (95% CI, 0.030–0.073), respectively], with negligible impact on controls.

Conclusions: The addition of a PRS for breast cancer to the well-established Tyrer–Cuzick and Gail models provides a substantial improvement in the prediction accuracy and risk stratification.

Impact: These findings could have important implications for the ongoing discussion about the value of PRS in risk prediction models and screening.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1158/1055-9965.epi-23-1432

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Nuffield Department of Population Health
Sub department:
Clinical Trial Service Unit
Role:
Author
ORCID:
0000-0002-8010-2503
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Nuffield Department of Population Health
Role:
Author
ORCID:
0000-0002-2930-605X
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Nuffield Department of Population Health
Sub department:
Clinical Trial Service Unit
Oxford college:
St John's College
Role:
Author
ORCID:
0000-0003-1177-6923
More by this author
Role:
Author
ORCID:
0000-0001-7420-7512
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Primary Care Health Sciences
Role:
Author
ORCID:
0000-0001-5595-8468


More from this funder
Funder identifier:
https://ror.org/054225q67
Grant:
C16077/A29186


Publisher:
American Association for Cancer Research
Journal:
Cancer Epidemiology, Biomarkers & Prevention More from this journal
Volume:
33
Issue:
6
Pages:
812-820
Publication date:
2024-06-03
Acceptance date:
2024-03-26
DOI:
EISSN:
1538-7755
ISSN:
1055-9965
Pmid:
38630597


Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP